Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 719 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Colitis Clear all
Completed Phase 1 Interventional

High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)

NCT05587673
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
Interventions
Methylprednisolone
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 25 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 1Phase 2 Interventional

Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy

NCT03847467
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
2'-Fucosyllactose, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 25 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Hartford, Connecticut • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

NCT03244644
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
60
States / cities
Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 23, 2026, 9:03 AM EDT
Withdrawn Not applicable Interventional

Extended Treatment With Vancomycin for Clostridium Difficile Colitis

NCT00861887
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Standard Vancomycin, Extended Vancomycin
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

NCT04004611
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Orange, California • San Francisco, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

NCT00628433
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, HE3286
Drug
Lead sponsor
Harbor Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Tucson, Arizona • Anaheim, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 23, 2026, 9:03 AM EDT
Withdrawn Phase 2 Interventional

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

NCT06646016
View directory record Official record
Conditions
Immune-related Colitis
Interventions
Methoxsalen, Infliximab, Vedolizumab
Drug
Lead sponsor
Therakos LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 23, 2026, 9:03 AM EDT
Completed No phase listed Observational

Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease

NCT01349504
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 23, 2026, 9:03 AM EDT
Not yet recruiting Phase 4 Interventional

Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis

NCT07059130
View directory record Official record
Conditions
Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
Interventions
Mirikizumab
Biological
Lead sponsor
Rubix LS
Industry
Eligibility
60 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT02407236
View directory record Official record
Conditions
Colitis, Ulcerative, Inflammatory Bowel Diseases
Interventions
Placebo IV, Placebo SC, Ustekinumab IV, Ustekinumab SC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
68
States / cities
Birmingham, Alabama • La Mirada, California • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis

NCT03006809
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal Microbiota Transplantation (FMT), OpenBiome, pretreatment antibiotics
Biological · Other
Lead sponsor
Najwa Elnachef
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

NCT05831189
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
RBX2660
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Withdrawn Phase 2 Interventional

Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis

NCT06521762
View directory record Official record
Conditions
Immune Checkpoint Inhibitor-Related Diarrhea and Colitis
Interventions
Etrasimod, Placebo, Corticosteroids
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

NCT01461317
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
La Jolla, California • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Not applicable Interventional

Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease

NCT00114803
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Calcitonin nasal spray (salmon)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 22 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT01959282
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, JNJ-54781532 25 mg once daily, JNJ-54781532 75 mg once daily, JNJ-54781532 150 mg once daily, JNJ-54781532 75 mg twice daily
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
La Jolla, California • Thornton, Colorado • Ann Arbor, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 23, 2026, 9:03 AM EDT
Not listed No phase listed Observational

Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI Biomarker Panel and Algorithm to Detect Mucosal Healing in Moderate to Severe Ulcerative Colitis Patients.

NCT04897282
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
UCRI
Diagnostic Test
Lead sponsor
Glycominds, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Obesity, Iron Regulation and Colorectal Cancer Risk

NCT03548948
View directory record Official record
Conditions
Colon Inflammation, Iron Malabsorption, Obesity, Diet Modification
Interventions
High heme iron diet, Low iron diet, Plant-based high non-heme iron diet
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
55 Years to 70 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 23, 2026, 9:03 AM EDT
Not yet recruiting Early Phase 1 Interventional

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

NCT06884748
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ursodiol 500 MG
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 9:03 AM EDT
Completed No phase listed Observational

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients

NCT00207688
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Infliximab 5 mg/kg, Infliximab 10 mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
44
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 23, 2026, 9:03 AM EDT
Not listed Phase 1 Interventional

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT05743010
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
APL-1401, Placebo
Drug
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Corona, California • Tampa, Florida • Marrero, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 23, 2026, 9:03 AM EDT
Enrolling by invitation No phase listed Observational

Improving the Quality of Care for Adults With Inflammatory Bowel Disease

NCT02791854
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
29
States / cities
Los Angeles, California • Newport Beach, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 23, 2026, 9:03 AM EDT
Completed Phase 3 Interventional

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

NCT05784246
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab IV, Mirikizumab SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
San Francisco, California • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 9:03 AM EDT